Work

Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer

Year: 2025

Type: article

Abstract: This retrospective cohort study examines the association of upfront treatment with enfortumab vedotin plus pembrolizumab with clinical outcomes for patients with advanced urothelial cancer.

Source: JAMA Oncology

DOI: 10.1001/jamaoncol.2025.4566

Authors: Ryan D. Chow, Ramy Sedhom, Ronac Mamtani

Institutions: University of Pennsylvania, University of Pennsylvania Health System, Abramson Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4416177012

FWCI: 3.455

Cites: 6

Cited by: 4

Related to: